Sort   by:  
 Page size 
MetabolomicsUntargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma
Neuroblastoma (NB) is the most common extracranial malignant tumor in children. Although the survival rate of NB has improved over the years, the outcome of NB still remains poor for over 30% of cases. A more accurate risk stratification remains a key point in the study of NB and the availability of...
2023-07-14 | MTBLS4294 | MetaboLights
MetabolomicsLipid metabolites as potential diagnostic and prognostic biomarkers for acute community acquired pneumonia
Early diagnosis of acute community-acquired pneumonia (CAP) is important in patient triage and treatment decisions. To identify biomarkers that distinguish patients with CAP from non-CAP controls, we conducted an untargeted global metabolome analysis for plasma samples from142 patients with CAP (CAP...
2016-08-11 | MTBLS354 | MetaboLights
MetabolomicsNon-invasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer
Lung cancer remains the most common cause of cancer deaths worldwide, yet there is currently a lack of diagnostic noninvasive biomarkers that could guide treatment decisions. Small molecules (<1500 Da) were measured in urine collected from 469 lung cancer patients and 536 population controls using u...
2014-05-06 | MTBLS28 | MetaboLights
MetabolomicsSerum Metabolomics Identifies Novel Prognostic Biomarkers in Amanita Poisoning

Background: Amanita poisoning causes 90-95% of global mushroom-related deaths, yet early prognostic biomarkers for Amanita poisoning are lacking.

Methods: 33 patients with Amanita poisoning were recruited and categorized into survival and death group. Multi...

2025-11-27 | MTBLS13397 | MetaboLights
MetabolomicsThe prognostic value of hydroxybutyrate dehydrogenase in diffuse large B-cell lymphoma

In our investigation, we examined biochemical parameters and identified hydroxybutyrate dehydrogenase (HBDH) as a significant predictor for diffuse large B-cell lymphoma (DLBCL) patients. A group of 100 patients was used to explore potential biomarkers related to progression-free survival (PFS). ...

2024-09-02 | MTBLS10446 | MetaboLights
MetabolomicsAn explainable prognostic prediction panel for sepsis based on serum amino acid profiles

Sepsis is a life-threatening syndrome requiring aggressive management, and novel noninvasive biomarkers to enable risk stratification of sepsis with high confidence and to predict the sepsis-related outcomes are urgently needed. 

A mass spectrometry–based quantitative method was used t...

2026-05-24 | MTBLS14567 | MetaboLights
MetabolomicsMutations-Upstream-of-Metabolomic-Signature Based Functional Analyses Identify Prognostic Biomarkers and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

Cross-talk among downstream regulatory networks of genome mutations has been the major hypothetical mechanism underlying poor prognosis and low-responsive rates for targeted therapy of pancreatic ductal adenocarcinoma (PDAC). By applying a causal inference-based mutation-upstream-of-the-metabolom...

2025-10-13 | MTBLS13111 | MetaboLights
MetabolomicsMutations-Upstream-of-Metabolomic-Signature Based Functional Analyses Identify Prognostic Biomarkers and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

Cross-talk among downstream regulatory networks of genome mutations has been the major hypothetical mechanism underlying poor prognosis and low-responsive rates for targeted therapy of pancreatic ductal adenocarcinoma (PDAC). By applying a causal inference-based mutation-upstream-of-the-metabolom...

2025-10-13 | MTBLS13127 | MetaboLights
MetabolomicsMutations-Upstream-of-Metabolomic-Signature Based Functional Analyses Identify Prognostic Biomarkers and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

Cross-talk among downstream regulatory networks of genome mutations has been the major hypothetical mechanism underlying poor prognosis and low-responsive rates for targeted therapy of pancreatic ductal adenocarcinoma (PDAC). By applying a causal inference-based mutation-upstream-of-the-metabolom...

2025-10-13 | MTBLS13116 | MetaboLights
MetabolomicsDistinct succinate modifying products are clinically diagnostic and prognostic biomarkers for fumarate hydratase deficient renal cell carcinoma

Germline or somatic loss-of-function of fumarate hydratase (FH) predisposes patients to an aggressive form of renal cell carcinoma (RCC). Since other than tumor resection, there is no effective therapy for FH-deficient RCC, a competent method for early diagnosis and for early detection of recurre...

2022-08-12 | MTBLS3628 | MetaboLights
Sort   by:  
 Page size